Robert (Bob) Abraham

Dr. Abraham is Executive Vice President and Head of Cancer Biology at Odyssey Therapeutics. Before that, he was most recently Chief Scientific Officer at Vividion Therapeutics. Prior to Vividion, he was the Senior Vice President and World-wide Head of the Oncology R&D group at Pfizer. From 2005-2009, he was the Head of Oncology Discovery Research at Wyeth. During his tenure at Wyeth and Pfizer, Dr. Abraham contributed to the development of eight FDA-approved cancer drugs. Prior to joining industry, Dr. Abraham was a Professor at the Sanford-Burnham-Prebys Medical Discovery Institute (SBPMDI) in La Jolla, CA, where he served as the Director of the NCI-designated SBPMDI Cancer Research Center. Prior to SBPDMI, he was endowed Chair in the Department of Pharmacology and Cancer Biology at the Duke University Medical Center. Prior to Duke University, Dr. Abraham held dual professorships in the departments of Immunology and Pharmacology at the Mayo Clinic in Rochester, MN. He maintains Adjunct Professor appointments at U.C. San Diego (Department of Pharmacology), and at the Sanford Burnham Prebys Institute.

Dr. Abraham began his career as an Academic Investigator, with enduring interests in cancer biology and immunology. His major research interests included characterization and functional analysis of the mammalian Target of Rapamycin (mTOR) signaling pathway, cancer metabolism, cellular signaling and DNA damage responses. Dr. Abraham has authored over 225 scientific publications, and his published work has been cited over 48,000 times.

Dr. Abraham received his B.S. in Biology from Bucknell University and his Ph.D. in Pharmacology at the University of Pittsburgh, and he completed his postdoctoral training in Pharmacology and Immunology at the Mayo Clinic.